Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Volumetric Modulated Arc Therapy for Radiosurgery of Brain Metastases: A Single-Center Study

Version 1 : Received: 2 August 2023 / Approved: 2 August 2023 / Online: 2 August 2023 (16:01:27 CEST)

A peer-reviewed article of this Preprint also exists.

Sánchez-Villalobos, J.M.; Serna-Berna, A.; Salinas-Ramos, J.; Escolar-Pérez, P.P.; Andreu-Gálvez, M.; Martínez-Alonso, E.; Pérez-Vicente, J.A.; Alcaraz, M. Volumetric Modulated Arc Therapy for Radiosurgery of Brain Metastases: A Single-Center Study. Appl. Sci. 2023, 13, 10097. Sánchez-Villalobos, J.M.; Serna-Berna, A.; Salinas-Ramos, J.; Escolar-Pérez, P.P.; Andreu-Gálvez, M.; Martínez-Alonso, E.; Pérez-Vicente, J.A.; Alcaraz, M. Volumetric Modulated Arc Therapy for Radiosurgery of Brain Metastases: A Single-Center Study. Appl. Sci. 2023, 13, 10097.

Abstract

Whole-brain radiation therapy and stereotactic radiosurgery are two treatment modalities commonly utilized to treat brain metastases (BMs). The aim of this study is to retrospectively analyze the main radio-oncologic and clinical-demographic aspects of a cohort of BM patients treated with Volumetric Modulated Arc Therapy for radiosurgery (VMAT-RS). This is a cross-sectional observational design study with retrospective review of medical records of patients with brain metastases treated with VMAT- RS between 2012 and 2018. Clinical and demographic data, with special attention to sex, age, primary tumor, brain tumor-related epilepsy (BTRE), number and brain location of BMs, Karnofsky Performance Status (KPS), the updated DS-GPA prognostic index and the survival estimated according to the Kaplan-Meier model from the date of radiosurgery were analyzed. One hundred and twenty-one patients with 229 BMs were treated with VMAT-RS. Patients presented 1-4 BMs, which were treated with 5 non-coplanar VMAT arcs. Sixty-eight percent of the patients had lung cancer and 35% of the BMs were in the frontal lobe. Proportion of local control was 88.5%. BTRE prevalence was 30.6%. The median survival time (MST) was 7.7 months. In the multivariate analysis of the Cox Regression model KPS70 (HRKPS<70=2.59; p=0.001) and higher DS-GPA (HRDS-GPAII =0.55, p=0.022; HRDS-GPAIII-IV =0.38, p=0.006) were associated with improved survival. In the univariate analysis, primary tumor, age and the presence of metastases in the posterior fossa (PFBMs) were also significative. In conclusion, the VMAT-RS is a technique with an overall survival comparable to other radiosurgery techniques. The median survival is significantly longer in those with higher KPS and DS-GPA. Other variables such as the type of primary tumor, age and PFBMs could also influence survival, although further studies are needed.

Keywords

VMAT; stereotactic radiosurgery; brain tumor-related epilepsy; overall survival; brain metastasis; brain location

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.